Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon.
about
Kasabach-Merritt phenomenon in a neonatal kaposiform haemangioendothelioma.Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon.Kasabach-Merritt phenomenon in Chinese children: Report of 19 cases and brief review of literatureClinical Outcomes for Systemic Corticosteroids Versus Vincristine in Treating Kaposiform Hemangioendothelioma and Tufted Angioma.Treatment of kaposiform hemangioendothelioma and tufted angioma.Kasabach-Merritt Phenomenon: Classic Presentation and Management Options.Medical therapy for pediatric vascular anomaliesPharmacological therapies for infantile hemangiomas: A clinical study in 853 consecutive patients using a standard treatment algorithmKaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in a neonate of life- and limb-threatening nature: A case reportSirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.Artesunate inhibits proliferation and invasion of mouse hemangioendothelioma cells in vitro and of tumor growth in vivo.Successful surgical management of congenital Kasabach-Merritt syndrome.Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: a Case Report and Review of the Literature.Musculoskeletal complication in kaposiform hemangioendothelioma without Kasabach-Merritt phenomenon: clinical characteristics and management
P2860
Q33417002-5B50A009-BCCD-46C4-B270-BE2209BE1CA0Q33423967-A7BDF2C9-16BA-4125-AED4-E9717ED68D22Q33425445-DCA8400F-093F-43B2-AC11-035D9D0A0C0FQ33432355-8E8AE623-5D94-41C6-B71B-F4E571A6651BQ33432670-1F03E876-D1C3-4E37-912F-B617FFD1BBFFQ33442416-4B6A2E6F-54F8-42AF-87DC-6A43974C5344Q33832551-FF7336A4-56F1-46D6-9D41-9B15DB2CEE2CQ35923763-93A980ED-4A15-472A-A82D-36E1806642D4Q36103408-4E504B9E-8D12-43BF-A099-BDF1D05A1EDEQ39155894-491A6639-9B12-45D4-8D66-7DF0D9C58618Q47166468-B51F8833-6C5E-40C7-952C-26917719770FQ53982575-6B42F4A6-6C13-4505-8501-BC8A8F014465Q55539095-359ED1ED-7685-4842-9A92-C036F95F5846Q58759095-EFE94FA1-03D4-40F8-BA12-8AD2C181D58A
P2860
Long-term outcome of vincristine-aspirin-ticlopidine (VAT) therapy for vascular tumors associated with Kasabach-Merritt phenomenon.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-term outcome of vincristi ...... h Kasabach-Merritt phenomenon.
@ast
Long-term outcome of vincristi ...... h Kasabach-Merritt phenomenon.
@en
type
label
Long-term outcome of vincristi ...... h Kasabach-Merritt phenomenon.
@ast
Long-term outcome of vincristi ...... h Kasabach-Merritt phenomenon.
@en
prefLabel
Long-term outcome of vincristi ...... h Kasabach-Merritt phenomenon.
@ast
Long-term outcome of vincristi ...... h Kasabach-Merritt phenomenon.
@en
P2093
P2860
P356
P1476
Long-term outcome of vincristi ...... th Kasabach-Merritt phenomenon
@en
P2093
Gloria Chocarro
Israel Fernandez-Pineda
Jose Bernabeu-Wittel
Juan Carlos Lopez-Gutierrez
P2860
P304
P356
10.1002/PBC.24543
P577
2013-04-22T00:00:00Z